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1. Introduction
Inflammation is the first response of the immune system 
to irritation or infection by germs. Inflammation has been 
considered as a major risk factor for cancer [1, 2]. Patients 
with inflammation, usually given treatment to slow or limit the 
process of tissue damage that occurs in the inflammatory area. 
The inflammatory mediator in the body is a prostaglandin, 
produced from arachidonic acid, has an essential role in the 
defence and repair of gastric epithelial cells, produces bicar-
bonate mucus, inhibits parietal cell secretion, retains mucosal 
circulation, and restitution of epithelial cells [3].
The commonly used drug classes are non-steroidal anti-
inflammatory drugs (NSAIDs). Diclofenac sodium is one of 
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Curcumin, well-known polyphenol drug shows great promise as a therapeutic agent. However, 
a major concern for this molecule is its low bioavailability. We have recently reported the use 
of mesoporous silica nanoparticles (MSN) to enhance curcumin bioavailability significantly. 
In the present work, we investigated anti-inflammatory effects of the curcumin-MSN and 
related side effects caused to the gastrointestinal tract and kidney, compared with curcumin 
and diclofenac sodium. The anti-inflammatory effect tests were performed by induction of 
carrageenan in Wistar rat feet. Ulcerogenic observations were performed macroscopically 
and microscopically. Kidney histopathology were performed on the average number of 
necrotic cells of the proximal tubule and distal tubules. There was anti-inflammatory activity 
in the administration of peroral curcumin and curcumin-MSN, in the absence of significant 
macroscopic and microscopic changes in the stomach organ. Curcumin-MSN showed a high 
anti-inflammatory activity comparable to diclofenac sodium but with a significantly enhanced 
biocompatibility.
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the most used NSAIDs. It was first introduced in the US in the 
1990s and has been consumed by more than 1 billion patients. 
It is also one of the most prescribed NSAIDs [4]. These drugs 
limit the activity of cyclooxygenase enzymes (COX) thus 
affects the formation of prostaglandin [1]. There are two types 
of COX, i.e. COX-1 and COX-2 enzymes [5]. The inhibitory 
action mechanisms of COX-1 enzymes causes gastrointestinal 
side effects and also through inhibition of COX-2 enzymes 
causes cardiovascular side effects. NSAIDs have major side 
effects on the gastrointestinal tract, particularly gastric irrita-
tion leading to the occurrence of peptic ulcers, and adverse 
reactions to the kidneys [5].
The adverse effects from the use of NSAIDs have intensi-
fying explorations of a natural anti-inflammatory agent with 
fewer side effects like curcumin. Curcumin is the active ingre-
dient that can be found in the dietary spice turmeric (Curcuma 
longa). There are numerous clinical trial and animal studies 
that confirm the benefit of curcumin as a therapeutic agent [6]. 
Curcumin acquires anti-inflammation, anti-oxidant and anti-
viral properties. It shows great promise for medication of various 
pro-inflammatory chronic illnesses such as Alzheimer’s dis-
ease, Parkinson’s disease, multiple sclerosis, epilepsy,cerebral 
injury, cardiovascular diseases, cancer, allergy, asthma, bron-
chitis, colitis, rheumatoid arthritis, renal ischemia, psoriasis, 
diabetes, obesity,depression, fatigue, and AIDS [7, 8].
Research conducted by Anand et  al [9] suggests that oral 
administration of curcumin is reported to have low levels of 
serum and tissue, as well as rapid metabolism and elimination. 
This is due primarily to the poor solubility of the curcumin. 
The problem of solubility can be overcome by several solutions 
such as the manufacture of nanoparticles [10] and the addition 
of a carrier substance like mesoporous silica nanoparticles [11].
Many researches showed the benefits from using 
mesoporous silica materials to increase the therapeutical 
effects of various of drugs namely doxorubicin [12], Paclitaxel 
[13, 14] and telmisartan (TEL) [15, 16]. These materials have 
received much attention as a drug delivery system due to its 
excellent properties such as very large surface area, porous 
structure, and ease of surface functionalization and biodeg-
radability [16]. These materials also show great promises for 
oral drug delivery system [15, 17, 18].
Various approaches have been used to develop a drug 
delivery system of curcumin by using mesoporous silica mat-
erials as a carrier. These approaches include the formation of 
guanidine functionalized PEGylated mesoporous silica nano-
particles (MSN) [19], lipid bilayer-coated curcumin-based 
MSN [20], curcumin-loaded silica encapsulated porous chi-
tosan [21], mesoporous silica coated curcumin lipid core [22], 
curcumin silica composites with double functionalization [23] 
and composite hydrogels of chitosan-MSN [24]. However, 
many of these synthesis methods require a complex procedure 
which limits their practical applications. A simple method to 
form curcumin-mesoporous silica materials is essential.
In addition, most of the studies on curcumin-mesoporous 
silica materials showed promising in vitro test results. The 
drug delivery systems enhanced curcumin’s therapeutic 
effects. Nevertheless, few in vivo study have been done to 
explore the actual effects of curcumin-mesoporous silica 
composite. A detailed in vivo study on curcumin-mesoporous 
silica materials is urgently required as proof of concept of the 
composite’s true potential.
Recently we have reported a facile method for the synthesis 
of mesoporous silica nanoparticles (MSN) as an oral drug car-
rier to increase the bioavailability of curcumin. Oral admin-
istration of curcumin-MSN with an equivalent dose of 10 
mg kg−1 resulted in curcumin concentration in mice’s blood 
three times higher than administration of curcumin only (free 
curcumin). The curcumin concentrations from the administra-
tion of free curcumin were very low at all-time points of the 
bioavailability test [25].
In the current study, we used the curcumin-MSN from our 
previous research to evaluate the anti-inflammatory capability 
and related biocompatibility. The anti-inflammatory effect of 
the curcumin-MSN was investigated by using an induction 
method of carrageenan to white male Wistar rat. The side 
effects of the curcumin-MSN to digestive and renal tract were 
studied through microscopic and macroscopic observation of 
related organs compared to free curcumin and commercial 
diclofenac sodium (NSAIDs).
2. Experimentals
2.1. Material and methods
Triblock copolymer EO106PO70EO106 (Pluronic F127, 
MW = 13 400), 1,3,5-trimethylbenzene, 3-aminopropyl 
triethoxysilane, phosphate buffer tablet and Tween 80, diclof-
enac sodium, carrageenan were purchased from Aldrich. A 
fluorocarbon surfactant (FC-4) was purchased from Yick-Vic 
Chemicals & Pharmaceuticals (HK) Ltd. All chemicals were 
used as received without purification. Curcumin extracts 
obtained from PT. Javaplant, Solo, Indonesia with 97% purity.
2.2. Animals
The experimental animals used in this study were white male 
Wistar rats, ages 6–8 weeks weighing 180–220 grams. Prior 
to use in the research, animals were adapted for one week 
under the same conditions or treatment, observed by weight 
weighing and behavioural observations. Animals are consid-
ered healthy and may be used for research if they do not show 
symptoms of illness and weight loss of no more than 10% of 
initial weight. All animal-related experiments were performed 
in full compliance to handling protocol of Ethics Committee 
in Gadjah Mada University, Indonesia (ethics committee 
approved No. 00094/04/LPPT/III/2017).
2.3. Synthesis of MSN
MSN were synthesized by adding 0.5 g of F127 as a primary sur-
factant, and also 1.4 g of FC-4 into 60 ml of HCl with a concentra-
tion of 0.02 M. The three components were mixed until a clear 
solution is formed. Then 0.5 g of TMB was added and followed 
by the addition of 3 g TEOS. The stirring was continued for 24 h at 
30 ◦C. From the stirring process, the solution was removed to an 
autoclave for the hydrothermal treatment at 100 ◦C for 24 h. From 
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the hydrothermal treatment, the product was separated by using 
a centrifugation method, washed and dried. Finally, a calcination 
method was used to remove the surfactants. The calcination was 
performed at 550 °C for 5 h [26].
2.4. Amine functionalization
MSN was modified with 3-aminopropyl triethoxysilane 
(APTES) to form amine functionalized MSN. MSN was 
weighed up to 0.6 g then added into 30 ml Toluene. The solu-
tion was stirred and heated. After the solution temperature 
reached 70 ◦C, then 0.2 g of APTES was added. The stirring 
was continued for another several hour. Finally, the product 
was separated by using a centrifugation method and dried [25].
2.5. Curcumin loading
Curcumin-MSN was synthesised by using a rotary evapo-
rator. Curcumin and MSN with ratio 1:4 (50 mg of curcumin 
and 200 mg of MSN) were mixed in 20 ml of ethanol. The 
mixture was first sonicated for 15 min. The solution was then 
heated and evaporated slowly at 55 ◦C. The process was per-
formed under vacuum condition and continued until the dry 
curcumin-MSN was obtained [25].
2.6. Anti-inflammatory activity
Wistar rats were fasted for 18 hours. The animals were divided 
into four groups each of 8. The first group is a control group. 
The control group (Group-1) was given water for injection 
(WFI). The second group (Group-2) was given free curcumin 
with concentration 10 mg kg−1. The third group (Group-3) 
received curcumin-MSN with concentration 50 mg kg−1. 
(50 mg curcumin-MSN contains 10 mg curcumin and 40 mg 
MSN). The last group (Group-4) was given diclofenac sodium 
with concentration 5 mg kg−1. Inflammatory testing was per-
formed by intraplantar injection of 1% carrageenan on the 
leg of the rat. Sixty minutes before induced carrageenan, the 
rats were first treated according to the prescribed group. The 
edema volume occurring was observed at 30, 60, 120, 180, and 
240 min, using a mercury plethysmometer. The percentage of 
Edema Rate (%ER) and the percentage anti-inflammatory can 
be determined by using the following equations (1) and (2).
%ER =
Vt − V0
V0
× 100%, (1)
Percentage of anti-inflammatory =
AUCp
AUCk
× 100%. (2)
Vt  is the rat leg edema volume at time t, V0 is the initial volume 
of the rat leg, AUCk is the area under the curve for the control 
group, and AUCp is the area under the curve for the treatment 
group.
2.7. Ulcerogenic test
Wistar rats were fasted for 18 hours. The animals were divided 
into four groups each of 8. The first group is a control group. 
The control group (Group-1) was given water for injection 
(WFI). The second group (Group-2) was given free curcumin 
with concentration 10 mg kg−1. The third group (Group-3) 
received curcumin-MSN with concentration 50 mg kg−1 
(50 mg curcumin-MSN contains 10 mg curcumin and 40 mg 
MSN). The last group (Group-4) was given diclofenac sodium 
with concentration 5 mg kg−1. Treatment was given for seven 
days, once per day. On the 8th day, animals are sacrificed and 
exposed on the surgical board, and the animal’s stomach is 
dissected, and the stomach is lifted out. The stomach is opened 
in a large arch, washed/cleaned with 0.9% NaCl and exposed 
over the white cork. The ulcerogenic effect was observed with 
gastric ulcer imaging, number of ulcers were calculated, and 
ulcer diameter was measured, then compared with the control 
group. The severity of the ulcer is expressed as the index of 
ulcer, which is calculated using equation (3)
Ulcer index = A+ B. (3)
A is average number of ulcer, B is average diameter of 
ulcer [27]. The index data were analysed statistically, while 
the histopathology data of gastric ulcers were analysed 
descriptively.
2.8. Kidney histopathology observation
Wistar rats were fasted for 18 h. The animals were divided 
into four groups each of 8. The first group is a control group. 
The control group (Group-1) was given water for injec-
tion (WFI). The second group (Group-2) was given free 
curcumin with concentration 10 mg kg−1. The third group 
(Group-3) received curcumin-MSN with concentration 50 mg 
kg−1. (50 mg curcumin-MSN contains 10 mg curcumin and 
40 mg MSN). The last group (Group-4) was given diclof-
enac sodium with concentration 5 mg kg−1. Treatment was 
given for seven days, once per day. On the 8th day, animals 
are sacrificed and exposed on the surgical board and then 
removed the kidney organ, placed in organ pots containing 
10% formalin buffer. Hematoxylin-eosin (HE) staining was 
performed on renal preparations, then renal histopathologic 
observation, i.e. the number of necrotic cells of the proximal 
tubes and the distal contrast tubules. Observations were made 
through five different fields of view in one slice with 1000 
times magnification.
2.9. Statistical analysis
Data obtained from each group were analyzed using one-way 
ANOVA and when data had significant differences between 
the group of treatments, the analysis was followed by The Post 
Hoc Duncan test.
3. Results and discussion
In this study, curcumin-MSN with ratio 1 to 4 were pre-
pared similarly to our previous methods. MSN with particle 
size around 100 nm, the pore size of 10 nm and cubic meso-
structure were functionalized with the amine group (APTES) 
before curcumin loading by using a rotary evaporator [25].
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3.1. Anti-inflammatory activity
The anti-inflammatory test of free curcumin, curcumin-MSN, 
and diclofenac sodium against edema inhibition in male Wistar 
rat was demonstrated by comparing the percentage rate of 
edema formation in rat feet and percentage of anti-inflamma-
tory properties. Figure 1 shows that the edema volume gradu-
ally increased and reached a maximum at around 30–60 min 
for group 2 and 3 and then decreased. Group 4 showed an 
almost similar trend. It reached a maximum of 30 min and then 
reduced. At the same period (180–240 min), the curcumin-
MSN treatment group (group-3) had the lowest percent age of 
the rate of formation of edema compared to the free curcumin 
group and diclofenac sodium.
Figure 1 shows that the rate of edema reached a minimum 
of three hours for group-3. This result is in agreement with the 
bioavailability test of curcumin release from MSN that showed 
a maximum concentration of three hours [25]. Our previous 
study showed that free curcumin and curcumin MSN had a 
similar trend. Both showed a maximum concentration of three 
hours. The concentration of curcumin from curcumin MSN 
were increased from 0.019 to 0.029µgml−1, while concentra-
tions of free curcumin were never above 0.05µgml−1. Thus 
the concentrations of curcumin from curcumin-MSN were 4 
to 6 times higher [25]. We believe the concentration of free 
curcumin was too small to generate the noticeable anti-inflam-
matory effect. That is why free curcumin did not show similar 
anti-inflammatory effects as curcumin-MSN.
The maximum concentration caused an optimum inhibition 
of edema. The value of the calculated area under the curve 
(AUC0−4) for group-3 and group-4 were quite similar. Table 1 
shows curcumin-MSN group (group-3) had the percent age of 
anti-inflammatory (21.06%), almost the same with group-4 
(diclofenac sodium): 23.33%. The lowest percent age was 
achieved by group-2 (free curcumin), indicating a higher 
anti-inflammatory curcumin-MSN effect compared with free 
curcumin.
Figure 1 indicates that curcumin-MSN had a relatively 
similar anti-inflammatory activity with diclofenac sodium. 
Curcumin-MSN showed a significantly enhanced perfor-
mance compared to free curcumin. We believe that this is 
due to the higher bioavailability of curcumin released from 
curcumin-MSN compared to free curcumin resulting in higher 
blood levels and higher anti-inflammatory effects. Free cur-
cumin has a rapid plasma clearance. It is important to make 
a complex of curcumin with other substance to increase the 
systemic bioavailability [28].
Curcumin-MSN as an oral drug delivery system increased 
the bioavailability of curcumin. The bioavailability study 
showed the curcumin concentration in mice’s blood from 
curcumin-MSN was three times higher compared to free cur-
cumin. During the bioavailability test, it was hard to detect the 
curcumin concentration from free curcumin [25]. The porous 
structure of MSN which in nano size limits the particle size of 
curcumin which influences the solubility. Loading curcumin 
into the pores of MSN changed the crystalline form into an 
amorphous structure. These factors synergistically enhanced 
the bioavailability of curcumin. Also, MSN protects curcumin 
from harsh acidic environments in the stomach [29].
Curcumin has multiple pathways to suppress inflamma-
tory process. It down-regulates cyclooxygenase-2 (COX-2), 
lipoxygenase, and inducible nitric oxide synthase (iNOS) 
enzymes. These conditions inhibit the inflammatory process 
and tumorigenesis [28]. However, curcumin alone had a lim-
ited anti-inflammatory activity due to its low bioavailability. 
The encapsulation of curcumin into MSN is very important to 
increase curcumin bioavailability and finally revealed its true 
potency. Curcumin released from MSN had an equally potent 
of anti-inflammation compared to diclofenac sodium.
3.2. Ulcerogenic test
3.2.1. Macroscopic observation results in rat’s stom-
ach. Macroscopic observation included observation of 
ulcers in rat stomach by counting the number of ulcers in the 
stomach. In this study, the results of the index calcul ation 
are presented in table 2, and the macroscopic images of the 
tested animals are shown in figure  2. Based on the calcul-
ation of index number of ulcer (table 2), it was found that in 
the curcumin-MSN group (group-3) the index value of ulcer 
(2.32± 0.82) was almost close to the control group index 
Figure 1. The relationship between the percentages of edema formation rate versus time (minutes). Note: Group-1: (control group) 
received WFI; Group-2: received curcumin 10 mg kg−1; Group-3: received curcumin-MSN 50 mg kg−1 (curcumin 10 mg and MSN 40 mg); 
Group-4: received diclofenac sodium 5 mg kg−1.
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(2.00± 0.00). The value of group-3 was lower compared to 
the group given free curcumin. The largest ulcer index was in 
the group of diclofenac sodium which was 6.16± 0.41. The 
ulcer index of group-4 was three times higher compared to 
group-3.The index number shows the severity of ulcers that 
occur in the stomach.
The control group showed normal or absent gastric 
mucosal features as shown in figure 2(A). In the administra-
tion of 10 mg kg−1 free curcumin showed a small number of 
ulcers (figure 2(B)), whereas on the 50 mg kg−1 curcumin-
MSN (figure 2(C)) showed even fewer gastric ulcers. Based 
on observations, ulcers were most common in groups given 
diclofenac sodium shown in figure 2(D).
The general mechanism of action of NSAIDs in reducing 
inflammation is by inhibiting the cyclooxygenase enzymes 
(COX). The inhibition of COX limits the formation of pros-
taglandin. Diclofenac works stronger against COX-2 com-
pared to COX-1 [30]. It is generally known that the use of 
diclofenac and other NSAIDs show side effects including car-
diovascular, gastrointestinal (GI) and hepatic complications. 
The inhibition of COX-1 and COX-2 eliminate protection in 
the gastric mucosa. In addition, one of the factors that might 
contribute to negative effects of diclofenac is the production 
of leukotriene. Leukotriene is one of eicosanoid inflammatory 
mediator. The increase in leukotriene level causes irritation 
on stomach lining [4]. Administration of diclofenac sodium 
in rats consecutively for seven days may lead to a much more 
severe gastric ulcer than the treatment group with curcumin 
and curcumin-MSN.
Based on research conducted by Srivastava et  al [31], it 
showed that curcumin has a more dominant effect on COX-2 
than COX-1. The drugs that have a stronger effect on COX-2 
than COX-1 or lower ratio COX-2/COX-1 has fewer effects on 
the stomach and kidney. That is why curcumin-MSN and free 
curcumin obtained fewer side effects than sodium diclofenac.
The minimum side effects of curcumin against gastric ulcer 
due to curcumin’s anti-inflammatory properties. It has been 
shown that curcumin showed therapeutic effects for a various 
gastrointestinal conditions such as dyspepsia, Helicobacter 
pylori infection, peptic ulcer, irritable bowel syndrome, 
Crohn’s disease, and ulcerative colitis [28]. Research by 
Pruksunand et  al [32] showed the efficacy of curcumin in 
removing ulcer. Phase II of a clinical trial of 45 patients with 
25 patients diagnosed with various size of ulcer between 
0.5 to 1.5 cm in diameter were given curcumin orally for 12 
weeks. The ulcers were disappeared after four weeks in 48% 
of patients. The other patients required 8–12 weeks to elimi-
nate the ulcer [32].
3.2.2. Microscopic observation of rat gastric. Microscopic 
observations included descriptive descent on the cross sec-
tion of rat gastric by looking at specific changes (figure 3). 
Microscopic observation of necrotic cells in the stomach with 
1000 magnification was done by the method of calculating five 
different fields of view at approximately 100 cells. The results 
of necrotic cells observation can be seen in table 3. Curcumin-
MSN had a very low of an average number of necrotic cells 
which is very close to the control Group 1. In contrast, sodium 
diclofenac had the highest number. The number of necrotic 
cells of group-4 was double than group-3. Figure 3 shows a 
picture of the defect in the mucosa that penetrates into the 
submucosa, muscularis propria or deeper.
Table 1. The value of AUC0–4 and percentage of anti-inflammatory.
Group
AUC0−4 (
µg min ml−1
)
Anti-inflammatory (%)
1 (WFI) 2.18± 0.17 —
2 (Curcumin) 1.82± 0.12 16.81
3 (Curcumin-MSN) 1.72± 0.07 21.06
4 (Diclofenac sodium) 1.67± 0.11 23.33
Note. Group-1: (control group) received WFI; Group-2: received curcumin 
10 mg kg−1; Group-3: received curcumin-MSN 50 mg kg−1 (curcumin 10 mg 
and MSN 40 mg); Group-4: received diclofenac sodium 5 mg kg−1.
Table 2. Ulcer index.
Group
Mean ulcer score
Ulcer  
index
Ulcer  
number
Ulcer  
diameter (mm)
1 (WFI) 1.00± 0.00 1.00± 0.00 2.00± 0.00
2 (Curcumin) 1.33± 0.81 1.33± 0.81 2.66± 1.62
3 (Curcumin-MSN) 1.16± 0.41 1.16± 0.41 2.32± 0.82
4 (Diclofenac sodium) 3.16± 0.41 3.00± 0.00 6.16± 0.41
Note. Group-1: (control group) received WFI; Group-2: received curcumin 
10 mg kg−1; Group-3: received curcumin-MSN 50 mg kg−1 (curcumin 10 mg 
and MSN 40 mg); Group-4: received diclofenac sodium 5 mg kg−1.
Figure 2. Macroscopic images of rat gastric mucosa. Group-1 (A), 
Group-2 (B), Group-3 (C) and Group-4 (D). The blue arrows point 
the ulcer (observed by magnifying glass). Note: Group-1: (control 
group) received WFI; Group-2: received curcumin 10 mg kg−1; 
Group-3: received curcumin-MSN 50 mg kg−1 (curcumin 10 mg and 
MSN 40 mg); Group-4: received diclofenac sodium 5 mg kg−1.
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In the control group showed microscopic images of cells 
in the gastric mucosa that were almost entirely normal or did 
not show a specific change and the average number of necrotic 
cells of 7.30± 3.06 is shown in figure 3(A). In the group given 
10 mg kg−1, free curcumin showed greater damage compared 
to the group of curcumin-MSN 50 mg kg−1. The obtained 
the average number of necrotic cells for curcumin and cur-
cumin-MSN were 10.86± 3.97 and 9.46± 2.40 respectively, 
as shown in figures  3(B), (C) and table  3. In comparison, 
diclofenac sodium with a dose of 5 mg kg−1 showed the most 
cell damage that is 22.76± 5.68.
Based on the ANOVA test, it was found that the calculation 
of the ulcer index on the gastric mucosa for the group given 
diclofenac sodium was significantly different from the other 
treatment groups (Fcount(25.698) > Ftable(3.10)). In addi-
tion, the mean number of gastric mucosal necrotic cells in the 
group given diclofenac sodium was also different from that 
of the other treatment groups (Fcount(19.173) > Ftable(3.10)). 
From the data above shows that administration of curcumin 
and curcumin-MSN peroral for seven days had milder side 
effects compared to diclofenac sodium.
The number of necrotic cells for group-2 and group-3 were 
quite similar. Both had a low number of necrotic cells which 
were very close to the control group. In contrast, group-4 had 
the highest number of necrotic cells. A number of necrotic 
cells in group-4 were double than that of group-2 and group-3. 
Many reasons cause necrotic cell death such as trauma, infec-
tion, toxins, and others. Necrotic cells are related to the 
cell swelling and rapid loss of membrane integrity [33, 34]. 
Necrosis is the death of cells and tissues in the living body. 
In necrosis the changes are evident in the cell nucleus with 
features such as loss of chromatin image, the core becomes 
wrinkled, not vesicular anymore, looks denser, dark black 
(pyknosis), the core is divided into fragments. The core is torn 
(karyorrhexis), the core no longer takes many colours on the 
colouring because it looks pale, unreal and eventually disap-
pears (karyolysis).
Curcumin with its anti-inflammatory activity has a unique 
ability to selectively kill cancer cells and not normal cells. 
Curcumin induces apoptosis of cancer cells but not normal 
cells [34]. It has been shown that curcumin did not affect 
normal rat hepatocytes. It showed a high biocompatibility to 
healthy cells [35].
A recent study showed that MSN is biocompatible and has 
a low risk of inflammation. It was shown that only mesoporous 
silica materials with larger particle size (>100 nm) and 
with a very high dosage caused a higher accumulation in 
the cells. The accumulation induces a significant release of 
reactive oxygen species (ROS) and oxidative stress and also 
an increase of inflammatory genes. The upregulation of the 
inflammatory genes was mediated through Nuclear factor κB
(NF− κB) and activator protein 1 (AP-1). These conditions 
promote autophagy’s pro activities which ultimately causes 
necrotic cell death [36]. In this study, we used MSN with 
particle size around 100 nm. That is why only minor necrotic 
cells were found.
Research by Çağıltay et al studied the effect of NSAIDs 
on the level of tumour necrosis factor (TNF). They com-
pared diclofenac sodium (100 mg), indomethacin (25 mg) 
and nabumethon (500 mg). Among these three, diclofenac 
sodium showed the highest level of TNF [37]. The increase of 
TNF causes accumulation of reactive oxygen species (ROS) 
which triggers activation of mitogen-activated protein kinase 
(MAPK) and disruption of mitochondrial membrane potential 
which ultimately leads to apoptosis and necrosis [38]. These 
conditions explain the highest number of necrotic cells from 
group-4 in Microscopic observation of rat gastric.
3.3. Histopathology test on rat kidney
Group 3 had a very low number of necrotic cells in prox-
imal tubules at 4.83 similar to group 2 (table 4). In contrast, 
diclofenac sodium caused the highest necrotic cells at 10.67. 
Figure 4 shows the fundamental differences between normal 
cells and necrotic cells in the proximal tubule section. In 
Figure 3. Microscopic images of rat gastric mucosa in the control 
group and treatment groups were performed in 5 fields of view 
with 1000 magnification and eosin hematoxylin staining. Group-1 
(A), Group-2 (B), Group-3 (C) and Group-4 (D). The yellow 
arrows point normal cells while the blue ones point necrotic cells. 
Note: Group-1: (control group) received WFI; Group-2: received 
curcumin 10 mg kg−1; Group-3: received curcumin-MSN 50  
mg kg−1 (curcumin 10 mg and MSN 40 mg); Group-4: received 
diclofenac sodium 5 mg kg−1.
Table 3. The average number of necrotic cells in rat stomach with 
five fields of view.
Group Average number of necrotic cells
1 (WFI) 7.30± 3.06
2 (Curcumin) 10.86± 3.97
3 (Curcumin-MSN) 9.46± 2.40
4 (Diclofenac sodium) 22.76± 5.68
Note. Group-1: (control group) received WFI; Group-2: received curcumin 
10 mg kg−1; Group-3: received curcumin-MSN 50 mg kg−1 (curcumin  
10 mg and MSN 40 mg); Group-4: received Diclofenac sodium 5 mg kg−1.
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normal cells, the nucleus of the cell is located right in the 
middle, and the edge of the cell is still intact, while the cells 
undergoing necrosis or ruptured cells, the cell nucleus is not 
visible.
Table 5 shows group-3 had an almost similar number of 
necrotic cells at 7.67 on distal tubule compared to group-2 
at 6.33. Group-4 had the highest number of necrotic cells at 
9.17. Figure  5 shows the fundamental differences between 
normal cells and necrotic cells in the distal part of the tubule.
Based on the ANOVA test of necrotic cells observa-
tion in the proximal tubule, Fcount (9.28) > Ftable (3.10) was 
obtained, meaning that there was a significant difference 
between treatment groups. Post Hoc Duncan test (α = 0.05) 
shows there was no significant difference in the control 
group, the curcumin extract group and the curcumin-MSN 
group, but differed significantly with the comparative group 
(diclofenac sodium), meaning that the curcumin and cur-
cumin-MSN extracts did not cause cellular damage to the 
renal organ compared with diclofenac sodium. ANOVA test 
results on necrotic cells observation on distal tubule, obtained 
Fcount(0.05) < Ftable(3.10) which means there is no significant 
difference between treatment groups.
The kidneys are the organs that regulate the internal chem-
ical fluid composition by filtration, reabsorption, and secre-
tion processes. The filtration takes place in the glomerulus, 
where blood plasma filtrate is formed. In the proximal tubule 
reabsorption of substances that are useful for the body’s 
metabolism to maintain the internal homeostasis environment, 
but it also removes the rest of the metabolism from blood to 
lumen tubules to be removed in the urine. Thus, when the 
fluid reaches the distal tubule, there are only substances that 
are not needed by the body to be excreted in the urine. The 
main target of acute tubular necrosis in cases of poisoning 
is the proximal tubule of the kidney. Tubule epithelial cells 
are easily destroyed by contact with toxin materials excreted 
through the kidneys. These toxin materials are the risk factor 
of nephrotoxicity. Nephrotoxicity is a drug or toxin-related 
damage kidney problems [39].
Curcumin can suppress the side effects of toxin molecules 
that mediate cellular oxidative stress and minimizes induction 
of ornithine decarboxylase (ODC), finally, removes nephro-
toxicity. Okazaki et  al showed that pretreatment with cur-
cumin reduces the nephrotoxicity of Ferric Nitrilotriacetate 
(Fe-NTA) (a known renal carcinogen). As a result, necrotic 
changes can be eliminated thus reduced the histopathological 
change in mice kidney [40]. Another study by Momeni et al 
also showed that curcumin improves kidney protection against 
sodium arsenite. Sodium arsenite caused a decrease in the 
diameter of the glomerulus and proximal tubule, glomerular 
area. However, for the curcumin-treated group showed no sig-
nificant different [41]. It can be concluded that curcumin with 
Table 4. Number of necrotic cells in proximal tubule.
Group
Number of necrotic 
cells in proximal tubule
1 (WFI) 3.50± 1.3
2 (Curcumin) 4.83± 0.75
3 (Curcumin-MSN) 4.83± 1.94
4 Sodium diclofenac 10.67± 4.50
Note. Group-1: (control group) received WFI; Group-2: received curcumin 
10 mg kg−1; Group-3: received curcumin-MSN 50 mg kg−1 (curcumin  
10 mg and MSN 40 mg); Group-4: received Diclofenac sodium 5 mg kg−1.
Figure 4. Microscopic overview of the Wistar rats in the proximal 
tubule section was performed in 5 fields of view with 1000 
magnification and eosin hematoxylin staining. Group-1 (A), Group-2 
(B), Group-3 (C) and Group-4 (D). Note: Group-1: (control group) 
received WFI; Group-2: received curcumin 10 mg kg−1; Group-3: 
received curcumin-MSN 50 mg kg−1 (curcumin 10 mg and MSN 
40 mg); Group-4: received diclofenac sodium 5 mg kg−1.
Table 5. Number of necrotic cells on distal tubule.
Group
Number of necrotic cells 
on distal tubule
1 (WFI) 4.67± 1.6
2 (Curcumin) 6.33± 3.5
3 (Curcumin-MSN) 7.67± 6.28
4 (diclofenac sodium) 9.17± 4.62
Note. Group-1: (control group) received WFI; Group-2: received curcumin 
10 mg kg−1; Group-3: received curcumin-MSN 50 mg kg−1 (curcumin  
10 mg and MSN 40 mg); Group-4: received Diclofenac sodium 5 mg kg−1.
Figure 5. Microscopic overview of the Wistar rats in the distal 
part of the tubule was performed in 5 fields of view with 1000 
magnification and eosin hematoxylin staining. Group-1 (A), 
Group-2 (B), Group-3 (C) and Group-4 (D). Note: Group-1: 
(control group) received WFI; Group-2: received curcumin 10  
mg kg−1; Group-3: received curcumin-MSN 50 mg kg−1 (curcumin 
10 mg and MSN 40 mg); Group-4: received diclofenac sodium  
5 mg kg−1.
Adv. Nat. Sci.: Nanosci. Nanotechnol. 9 (2018) 035007
L Hadisoewignyo et al
8
its anti-oxidant properties does not cause side effects to the 
kidney, in fact, it supports kidney protection. In contrast, the 
use of a combination of NSAIDs enhanced nephrotoxic risk. 
The delivery of these drugs causes competition for transport 
protein in the proximal tubular cells. This condition leads to 
increase of toxin concentration. The accumulation of these 
substance in cytoplasm causes phospholipid membrane inter-
ruption, oxidative stress and mitochondrial injury which ulti-
mately causes proximal tubular necrosis [39].
In general, curcumin-MSN had a better performance of the 
anti-inflammatory activity and safety features compared to free 
curcumin. Mesoporous silica nanoparticles not only contrib-
uted to the enhancement of curcumin bioavailability but might 
also support the reduction of inflammation effects. Research 
by Pelle et  al showed that silica particle could be used for 
wound healing in the skin and liver of rats. The absorption of 
nanoparticles caused tissues adhesion and sealed the wound. 
After seven days, there was no sign of wound reopening, path-
ological inflammation and necrosis [42, 43]. Other research by 
Li et al shows the high biocompatibility of curcumin-loaded 
mesoporous silica incorporated nanofiber mats for hemostasis 
and anti-bacterial treatment [44].
Compared to other NSAIDs, diclofenac has relatively low-
risk factors for GI toxicity and cardiovascular diseases (CVD) 
[4]. Still, curcumin-MSN had an equally potent in inflam-
matory activity and fewer side effects compared to diclof-
enac sodium. Also, unlike other drugs that selectively inhibit 
COX-2 but causes a higher risk of heart attacks, it has been 
reported that curcumin shows effects against CVD. Curcumin 
inhibits NF− κB. NF− κB is responsible for inducing CRP. 
CRP is an inflammatory marker and also a risk factor for 
CVD [45]. This makes curcumin-MSN as a high potent anti-
inflammatory agent with a minimum risk compared to others 
NSAIDs.
4. Conclusion
The administration of peroral curcumin-MSN (50 mg kg−1) 
caused strong anti-inflammatory activity that is almost sim-
ilar to diclofenac sodium. The administration free curcumin 
(10 mg kg−1) and curcumin-MSN (50 mg kg−1) proved to pro-
vide no significant macroscopic and microscopic changes to 
the gastric organ. While giving peroral of diclofenac sodium 
(5 mg kg−1) showed significant changes in macroscopic and 
microscopic stomach characterised by the occurrence of gas-
tric ulcers and necrotic cells, suggesting the use of curcumin 
and curcumin-MSN had fewer side effects compared with 
administration diclofenac sodium (NSAID group drugs) in 
the treatment of inflammation. The administration of peroral 
curcumin extract and curcumin-MSN had a minor effect of 
necrosis of proximal tubule cells and distal tubule cells. Thus, 
unlike general NSAIDs that might cause gastro intestine tox-
icity and related damage kidney problems, curcumin-MSN 
can be considered as a safe drug. Therefore, we have designed 
an oral curcumin-MSN drug delivery system which shows a 
high potency for anti-inflammation with very low side effects. 
The strong anti-inflammatory properties open the possibility 
of using this drug for medication of inflammation-related dis-
eases such as cancer, diabetes and many others.
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